Chen J T, Tatsuki Y, Hirai Y, Hasumi K
Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
Gan To Kagaku Ryoho. 1993 Feb;20(2):265-70.
Twenty-two patients with ovarian cancer stage III and IV received combination chemotherapy with CDDP, adriamycin (ADM) and cyclophosphamide (CPM), and were studied for response and side-effects. Patients were divided into two groups according to the following CDDP infusion schedules. (CAP 1) CDDP 7mg/sqm/8 hrs/saline 500 ml/d1-d10, ADM 35 mg/sqm/d1, CPM 350 mg/sqm/d1: 8 cases; (CAP 2) CDDP 70 mg/sqm/2 hrs/d1, ADM 35 mg/sqm/d1, CPM 350 mg/sqm/d1: 14 cases. The overall response rate (CR + PR) was 62.5% in CAP 1, and 50% in CAP 2 (on statistical difference: NS). The 3-year survival rate was 54.7% in CAP 1 and 38.5% in CAP 2 (NS). Side effects of nausea, vomiting and nephrotoxicities were remarkably reduced in CAP 1. These data suggest that lower concentration and longer infusion time of CDDP administration increases the therapeutic index. This infusion schedule is suitable for chemotherapy at home or on an outpatient clinic basis, especially in patients with ovarian cancer.
22例III期和IV期卵巢癌患者接受了顺铂、阿霉素（ADM）和环磷酰胺（CPM）联合化疗，并对疗效和副作用进行了研究。根据以下顺铂输注方案将患者分为两组。（CAP 1）顺铂7mg/平方米/8小时/生理盐水500ml/d1 - d10，阿霉素35mg/平方米/d1，环磷酰胺350mg/平方米/d1：8例；（CAP 2）顺铂70mg/平方米/2小时/d1，阿霉素35mg/平方米/d1，环磷酰胺350mg/平方米/d1：14例。CAP 1组的总缓解率（CR + PR）为62.5%，CAP 2组为50%（无统计学差异：NS）。CAP 1组的3年生存率为54.7%，CAP 2组为38.5%（无统计学差异）。CAP 1组中恶心、呕吐和肾毒性等副作用明显减少。这些数据表明，较低浓度和顺铂较长时间的输注可提高治疗指数。这种输注方案适用于家庭化疗或门诊化疗，尤其是卵巢癌患者。
